Overview

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors

Phase:

Phase 1

Details

Lead Sponsor:

Minneamrita Therapeutics LLC

Collaborator:

Translational Drug Development